Article

Alcon ophthalmic manufacturing plant opens in Singapore

Alcon Laboratories opened the doors this week to its new state-of-the-art ophthalmic pharmaceutical manufacturing facility in the Tuas Biomedical Park in Singapore.

 

Singapore-Alcon Laboratories opened the doors this week to its new state-of-the-art ophthalmic pharmaceutical manufacturing facility in the Tuas Biomedical Park in Singapore.

The new facility will allow Alcon to be closer to its growing base of customers and patients throughout Asia, according to the company.

“The need for quality eye care is increasing rapidly across Asia as the population grows and ages,” said Roy Acosta, area president, Alcon Asia-Pacific. “With the opening of this new manufacturing facility, Alcon is making a strong investment in the future of our business in Asia, and ensuring that our innovative products are readily available to those who need them.”

Construction of the 330,000-square-foot facility began in 2009, and cost about S$200 million to build.

The plant will produce ophthalmic pharmaceutical products that address eye conditions, such as glaucoma, dry eye, allergies, and bacterial infections.

“Alcon has more than 20 manufacturing facilities around the world, which use state-of-the-art technology and adhere to the strictest quality standards,” Acosta said. “We are proud to transfer those same capabilities to serve our customers right here in Asia with locally manufactured products.”

 

The company already has experience in operating a manufacturing plant in Singapore. In 2005, Alcon opened a contact lens manufacturing facility in the Tuas Biomedical Park to meet the growing demand for dailies contact lenses, the company reported.

Currently, the new facility employs about 150 associates, and it is expected to continue to grow as production increases.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.